Rapport Therapeutics’ IPO came with a concurrent private placement that boosted the biotech’s cash haul. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S.
The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News.
Recent Posts
Categories
Related Articles
These 3 Mindset Shifts Will Help Providers Deliver Consumer-Driven Care, Investor Says
One of the most important things providers can do on the journey...
Top Hospitals for Pacemaker Implantation Surgery in India: What you need to know?
Pacemaker implantation is a life-saving procedure for people with irregular heart rhythms....
Links
When is a public health problem a crisis? LA has the worst...
Remembering Thomas E. Kurtz
By MIKE MAGEE This has been a challenging week for me, but...
Leave a comment